Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.09 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 7 Parkinson's papers of 66 | 0.73 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 2855
Sealed predictions
- ZFYVE26 in dopamine neurons, braak+0.25 (p 0.508) → -0.26 (p 0.493)receipt 2862
Swarm cases
receipt 2862: ZFYVE26 in dopamine neurons, braak
- power
- full sample +0.03 (p 0.901, n 18), 95% CI -0.44 to +0.49. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.05 (p 0.840, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.02 (p 0.949, n 18). could be the mix.
- skeptic
- leave-one-out range -0.12 to +0.13, sign flips 5; without severely affected donors +0.03 (p 0.901, n 18). fragile.
- cell type
- strongest in astrocytes: -0.59 (p 0.0099, n 18) vs +0.03 in dopamine neurons. proposing astrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ZFYVE26 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up ZFYVE26 · astrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) +0.20 p 0.477 (needs p < 6.4e-4)
Receipts
loading the receipts